Literature DB >> 16678003

Drug-associated disease: cytochrome P450 interactions.

Henry J Mann1.   

Abstract

Critically ill patients generally are older, frequently have organ failure, and commonly receive multiple medications, all of which make them susceptible to adverse effects of drugs. Drug interactions are a common adverse effect, and many are predictable based on understanding the mechanisms that underlie drug interactions. This article identifies commonly used medications in critically ill patients and the associated drug interactions that may occur with emphasis on the cytochrome P450 enzyme system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678003     DOI: 10.1016/j.ccc.2006.02.004

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  12 in total

1.  Evaluation of three brands of drug interaction software for use in intensive care units.

Authors:  Adriano Max Moreira Reis; Silvia Helena De Bortoli Cassiani
Journal:  Pharm World Sci       Date:  2010-10-21

Review 2.  Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Authors:  Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

Review 3.  Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.

Authors:  Stéphane Mouly; Christophe Meune; Jean-François Bergmann
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

Review 4.  Sex differences in the expression of hepatic drug metabolizing enzymes.

Authors:  David J Waxman; Minita G Holloway
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

5.  Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil.

Authors:  Adriano Max Moreira Reis; Silvia Helena De Bortoli Cassiani
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

6.  EPMA position paper in cancer: current overview and future perspectives.

Authors:  Godfrey Grech; Xianquan Zhan; Byong Chul Yoo; Rostyslav Bubnov; Suzanne Hagan; Romano Danesi; Giorgio Vittadini; Dominic M Desiderio
Journal:  EPMA J       Date:  2015-04-15       Impact factor: 6.543

7.  Do Sex Differences in Respiratory Burst Enzyme Activities Exist in Human Immunodeficiency Virus-1 Infection?

Authors:  Mathias Abiodun Emokpae; Beatrice Aghogho Mrakpor
Journal:  Med Sci (Basel)       Date:  2016-11-15

8.  Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay.

Authors:  Young-Hoon Kim; Young-Ji Bae; Hyung Soo Kim; Hey-Jin Cha; Jae-Suk Yun; Ji-Soon Shin; Won-Keun Seong; Yong-Moon Lee; Kyoung-Moon Han
Journal:  Biomol Ther (Seoul)       Date:  2015-09-01       Impact factor: 4.634

Review 9.  Understanding and preventing drug-drug and drug-gene interactions.

Authors:  Cara Tannenbaum; Nancy L Sheehan
Journal:  Expert Rev Clin Pharmacol       Date:  2014-04-19       Impact factor: 5.045

10.  Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.

Authors:  Mahmoud A El-Ghiaty; Sherif M Shoieb; Ayman O S El-Kadi
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.